[{"orgOrder":0,"company":"University of Georgia Research Foundation","sponsor":"AN2 Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Licensing Agreement","leadProduct":"AN15368","moa":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"University of Georgia Research Foundation","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"University of Georgia Research Foundation \/ AN2 Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"University of Georgia Research Foundation \/ AN2 Therapeutics"}]

Find Clinical Drug Pipeline Developments & Deals for AN15368

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          University of Georgia Research Foundation

                          Country arrow
                          2024 ACI Convention
                          Not Confirmed

                          University of Georgia Research Foundation

                          Country arrow
                          2024 ACI Convention
                          Not Confirmed

                          Details : The agreement aims to advance the development of AN2-502998 (formerly known as AN15368), a boron-based small molecule therapeutic under development for the treatment of Chagas disease.

                          Brand Name : AN2-502998

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          October 18, 2023

                          Lead Product(s) : AN15368

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : IND Enabling

                          Sponsor : AN2 Therapeutics

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank